Heregulins are a group of growth factors that play diverse and critical roles in the signaling network of the human epidermal growth factor receptor (HER or EGFR) superfamily. Our earlier studies have shown that recombinant heregulinb1 (HRG) induces apoptosis in SKBr3 breast cancer cells that overexpress HER2. Here we report molecular mechanisms of HRG-induced apoptosis. HRG treatment of SKBr3 cells for 72 h decreased the level of Bcl-2 protein. HRG treatment led to degradation of poly (ADP-ribose) polymerase (PARP) and activated both caspase-9 and caspase-7. No signi®cant activation of caspase-3, -6, or -8 was detected. Expression of exogenous caspase-7 by adenovirus-caspase-7 (Ad-casp-7) in SKBr3 cells resulted in apoptosis, which mimicked the eect of HRG treatment. Expression of exogenous caspase-7 had no impact on Bcl-2 expression, but promoted PARP degradation. Two highly selective inhibitors of protein kinase C (PKC), GF109203X (GF) and Ro318425 (Ro), signi®cantly enhanced HRG-induced apoptosis as determined by¯ow cytometric analysis and DNA fragmentation assay. Accordingly, the PKC inhibitor GF further decreased the level of Bcl-2 protein and further degraded PARP in HRG-treated cells. Assay of PKC activity indicated that HRG activated PKC in SKBr3 cells, predominantly aecting the PKCa isoform. To con®rm which PKC isoform(s) mediated potentiation of HRG-induced apoptosis, the pro®le of PKC isoforms was measured in SKBr3 cells. Five PKC isoforms, PKCa, PKCi, PKCz, PKCl, and PKCd as well as their receptors (RACK1) were expressed in this cell line. Treatment with PKC inhibitors GF and Ro decreased protein levels of both PKCa and PKCd at 24 h. PKCa levels were still depressed at 72 h. GF and Ro had little eect on the expression of other PKC isoforms. An inhibitor of classical PKC isoforms (Go6976) enhanced HRG-induced apoptosis, whereas the PKCd selective inhibitor rottlerin did not. As PKCa was the only classical isoform expressed in SKBr3 cells, the eect of Go6976 on HRG-induced apoptosis largely related to inhibition of PKCa. Constitutive expression of wild-type PKCa attenuated the apoptosis produced by HRG and GF. Consequently, HRG-induced apoptosis in SKBr3 cells appeared to involve down-regulation of Bcl-2 protein, activation of caspase-9 and caspase-7, and degradation of PARP. Inhibition of PKC function enhanced HRGinduced apoptosis, leading to synergistic down-regulaIntroduction Heregulin (HRG) was cloned and characterized during a search for a ligand reactive with the HER-2 tyrosine kinase growth factor receptor (Holmes et al., 1992; Wen et al., 1992) . Currently, four distinct genes are included in the family of heregulin (HRG) proteins, HRG1, HRG2, HRG3 and HRG4 (Carraway et al., 1997; Chang et al., 1997; Zhang et al., 1997; Harari et al., 1999) . HRG1 has been studied most extensively and exhibits over 15 splice isoforms (Alroy and Yarden, 1997; Riese and Stern, 1998) . The heregulins cannot bind to HER-2 alone, but are natural ligands for HER3 and HER4 (Falls et al., 1993; Marchionni et al., 1993; Plowman et al., 1993; Carraway et al., 1994; Tzahar et al., 1994) . The heregulins signal preferentially through heterodimers of HER2-HER3 or HER2-HER4 Alroy and Yarden, 1997; Riese and Stern, 1998) .
HRG signaling is involved in both physiologic and pathologic processes including embryogenesis of the brain and heart (Adlkofer and Lai, 2000; Alroy and Yarden, 1997; Riese and Stern, 1998) , cell proliferation (Lewis et al., 1996; Beerli and Hynes, 1996; Aguilar et al., 1999; Weinstein and Leder, 2000) , oncogenesis (Krane and Leder, 1996; Alroy and Yarden, 1997; Weinstein and Leder, 2000) , angiogenesis (BagheriYarmand et al., 2000; Yen et al., 2000) , motility/ invasion (Xu et al., 1997; Tan et al., 1999; Hijazi et al., 2000) , receptor tracking (Zhou and Carpenter, 2000) , cell cycle arrest Peles et al., 1992; Le et al., 2000a) ; dierentiation Peles et al., 1992; Jones et al., 1996; Le et al., 2000a) , and apoptosis (Daly et al., 1997; Grimm et al., 1998; Weinstein et al., 1998; Daly et al., 1999; GuerraVladusic et al., 1999; Le et al., 2000a) . HRGs can have three dierent biological roles in vivo and in vitro, depending on the combination of HER receptors expressed and the cell type investigated. Although HRGs can inhibit tumor growth through induction of cell cycle arrest, cell dierentiation, or apoptosis (Le et al., 2000a) , they are also able to promote tumor formation by increasing cell proliferation, angiogenesis, or motility/invasion.
Several research groups, including our own, have observed that HRGb1 (hereafter named heregulin or HRG) is able to inhibit the growth of breast and ovarian cancer cells that overexpress HER2 Peles et al., 1992; Daly et al., 1997; Xu et al., 1997; Weinstein et al., 1998) . We have shown that HRG can inhibit growth of SKBr3 cells, a human breast cancer cell line that overexpresses HER2, and that growth inhibition relates to induction of apoptosis, cell cycle G2-M arrest, and cell dierentiation (Le et al., 2000a) . Currently, little is known about molecular mechanisms that regulate HRG-induced apoptosis. In this report, we have shown that HRG can induce apoptosis through a mitochondrial pathway. HRG decreases Bcl-2 expression, activates caspase-9 and caspase-7, and degrades poly (ADPribose) polymerase (PARP) in SKBr3 cells. Furthermore, inhibition of protein kinase C (PKC) is able to potentiate HRG-induced apoptosis. This study also identi®es PKCa as the major isoform of PKC involved this process.
Results

Growth inhibitory role of heregulin in HER2-overexpressing cancer cells
We have previously demonstrated that treatment with HRG for 72 h induced apoptosis in about 12% of SKBr3 cells that overexpress HER2 (Le et al., 2000a ). Here we have tested the eect of heregulin on three additional breast cancer cell lines that endogenously over-express HER2 and ®ve breast cancer cell lines that express low levels or non-detectable levels of HER2. The results are summarized in Figure 1a , which indicated that the biological response to heregulin in SKBr3 breast cancer cells could be reproduced in another HER2-over-expressing breast cancer cell line, AU565. HRG induced 13.5% apoptosis in AU565 at 72 h (Figure 1b) . Two other HER2-over-expressing cell lines (MDA-MB-453 and BT-474) did not exhibit apoptosis after heregulin treatment. Similarly, heregulin treatment failed to produce apoptosis in ®ve breast cancer cell lines that express low levels or non-detectable levels of HER2 (Figure 1a ). These data suggest that: (1) heregulin induces apoptosis at higher frequency in human breast cancer cell lines that over-express HER2 (2/4) than in HER2-low-expressing cell lines (0/5); (2) Heregulininduced apoptosis occurs in some, but not all, breast cancer cell lines that over-express HER2. Our previous observations with ovarian cancer cell lines also supported these conclusions. Ovarian cancer cell lines with a high level of HER2 relative to HER3 or HER4 were growth inhibited, whereas cell lines with lower levels of HER2 were growth stimulated by heregulin (Xu et al., 1999) . Taken together, these results document the ability of heregulin to inhibit growth and induce apoptosis in HER2-overexpressing cancer cells.
Decrease of Bcl-2 protein expression by HRG
To explore mechanisms that might contribute to the induction of apoptosis, levels of pro-apoptotic and anti-apoptotic proteins were measured in the human breast cancer cell line SKBr3, which over-expresses HER2. When SKBr3 cells were treated with recombinant HRGb1, Bcl-2 expression was decreased by as much as ®vefold (Figure 2a,b) . By contrast, Bax levels were not aected by HRGb1 treatment (data not shown). In other systems, enforced-expression of HRGb2b has been shown to down-regulate Bcl-2 . Thus, treatment with HRG, under conditions that induced apoptosis, decreased levels of the anti-apoptotic protein Bcl-2, but did not aect levels of the pro-apoptotic protein Bax.
Activation of caspase-7 and caspase-9 by HRG Caspase-3, caspase-6, and caspase-7 are the known executor or eector caspases (Earnshaw et al., 1999; Utz and Anderson, 2000) . Activation of these three eector caspases was measured by Western blot analysis in SKBr3 cells treated with HRG. With two dierent anti-caspase-7 antibodies, we found that caspase-7, another eector caspase, was proteolytically cleaved in SKBr3 cells that were undergoing apoptosis after treatment with HRG ( Figure 3a , Lane 2). The active cleavage product of the caspase-7 pro-enzyme was increased by 2.5-fold in HRG-treated cells when compared to untreated cells (Figure 3b ). Preliminary results from both Western blot analysis and caspase activity assays indicated that two of the eector caspases, caspase-3 and caspase-6, were not signi®-cantly activated (Figure 4a,b) . Similar results were obtained with a lysate from paclitaxel-treated SKBr3 cells (Figure 3a , Lane 3), consistent with earlier reports that paclitaxel treatment activates caspase-7 (Panvichian et al., 1998) . Our results suggest that HRG-induced apoptosis is associated with activation of caspase-7. Cleavage of caspase-9 and caspase-8 initiate further caspase cleavage in the mitochondrial and death domain-mediated apoptotic pathways, respectively (Gottlieb, 2000) . Down-regulation of Bcl-2 in HRGtreated SKBr3 cells suggested that HRG-induced apoptosis might be related to the mitochondrial pathway. As shown in Figure 3c , cleaved caspase-9 was detected in HRG-treated cells, consistent with the production of apoptosis through a mitochondrial pathway.
To further con®rm the role of caspase activation in HRG-induced apoptosis, SKBr3 cells were incubated prior to treatment with HRG with the caspase inhibitor III (Calbiochem), a pan-inhibitor of caspases. As expected, treatment with the pan-caspase inhibitor abrogated HRG-induced apoptosis (Figure 3d ). Speci®c inhibitors of caspase-3 and caspase-6 had, however, no eect on HRG-induced apoptosis (data not shown). Taken together, these data strongly suggest that HRG-induced apoptosis involves caspase-9 as an initiator and caspase-7 as an eector.
Degradation of PARP by HRG
PARP cleavage by eector caspases is considered to be a hallmark of apoptosis (Earnshaw et al., 1999) . As shown in Figure 4c ,d, HRG substantially decreased levels of full-length PARP (116-kDa band). Lysates of HRG-treated SKBr3 cells consistently degraded ®ve-fold more PARP than did untreated cells (Figure 4d) . However, the cleaved PARP fragment (85-kDa band) was not detectable in the HRG-treated cells.
Induction of apoptosis in SKBr3 cells by exogenous expression of caspase-7
Caspase-7 was activated during HRG-induced apoptosis as described above, but it was not certain that it played a critical role in this process. Consequently, exogenous caspase-7 was expressed in SKBr3 cells to determine whether this would induce apoptosis. As adenovirusmediated gene transfer has been highly successful in SKBr3 cells (Le et al., 1998) , we infected cells with adenovirus-caspase-7 (Ad-casp-7) (Marcelli et al., 1999) and measured caspase-7 expression, apoptosis, Bcl-2 expression and PARP cleavage. At dierent multiplicity of infection (MOI) (Figure 5a ), increased caspase-7 expression could be detected at 10 MOI and reached maximal levels at 100 MOI. For subsequent studies, 30 MOI was chosen. Infection with Ad-casp-7 at 30 MOI induced about 10% apoptotic cells, which mimicked HRG-induced apoptosis in SKBr3 cells (Figure 5b ). Control adenovirus at 30 MOI induced no apoptosis (Le et al., 1998) . Unlike HRG, Ad-casp-7 alone did not alter Bcl-2 levels ( Figure 5c , Lane 5). Like HRG, Ad-casp-7 alone did degrade PARP (Figure 5d ). Degradation of PARP in Ad-casp-7 infected cells was less than that in HRG-treated cells, consistent with the possibility that HRG might cleave PARP through additional pathways ( Figure 5d ). Additionally, a combination of HRG and Ad-casp-7 resulted in greater induction of apoptosis in SKBr3 cells than did infection with Ad-caspase-7 alone ( Figure 5b ). Thus, HRG-induced apoptosis may proceed only in part through caspase-7.
Potentiation of HRG-induced apoptosis by PKC inhibitors
PKC activity in SKBr3 cells was activated by HRG treatment at 72 h, which was demonstrated by a PKC enzymatic assay (Figure 6a ). GF109203 (GF) (Toullec et al., 1991) and Ro318425 (Ro) (Wilkinson et al., 1993) are highly selective PKC inhibitors. A combination of GF and HRG induced 20.7% apoptosis in SKBr3 cells as assessed by¯ow cytometry ( Figure 6b ) and greater apoptosis as assessed by DNA fragmentation analysis (Figure 6c ), whereas GF alone and HRG alone induced 3.2% and 10.8% apoptosis, respectively ( Figure 6b ). Similarly, a combination of Ro and HRG resulted in 20.3% apoptosis (Figure 6b ). These data suggest that impairment of PKC function in SKBr3 cells can enhance HRG-induced apoptosis.
Synergistic down-regulation of Bcl-2 and degradation of PARP after treatment with a combination of HRG and a PKC inhibitor
Since HRG-induced apoptosis involved down-regulation of Bcl-2 expression, activation of caspase-7, and degradation of PARP, we studied the eect of the PKC inhibitor GF in combination with HRG on each of these proteins. As shown in Figure 6a , HRG decreased levels of Bcl-2, whereas GF alone had no eect on Bcl-2 expression. Combination of HRG and GF resulted in synergistic down-regulation of Bcl-2 expression ( Figure 7a ). Consistent with potentiation of HRG-induced apoptosis by the PKC inhibitor, a combination of HRG and GF exerted a synergistic eect on degradation PARP (Figure 7b ). We did not, however, observe a signi®cantly synergistic eect on activation of caspase-7 using a combination of HRG and PKC inhibitor GF (data not shown).
The profile of PKC isoforms in SKBr3 cells
GF and Ro are PKC inhibitors that aect multiple isoforms of the enzyme. To determine which isoform of PKC was involved in potentiation of HRG-induced apoptosis, we ®rst identi®ed the pro®le of PKC isoforms in SKBr3. Using a panel of monoclonal antibodies against dierent PKC isoforms, ®ve PKC isoforms could be detected in SKBr3 cells by Western blot analysis (Figure 8 ). The ®ve isoforms were PKCa (the only classical PKC expressed in the cells, Figure  8a ), PKCi (atypical, Figure 8b ), PKCz (atypical, Figure 8b ), PKCl (atypical, Figure 8b ), and PKCd (the only novel PKC expressed in the cells, Figure 8c ). In addition, two regulatory proteins related to PKC were also expressed in SKBr3 cells (Figure 8d ): a receptor for activated C kinase (RACK1) and diacylglycerol kinase (DGK) y (type V).
Expression of the ®ve isoforms was measured after incubation with the pan-PKC inhibitors. As shown in Figure 9a , treatment with GF and Ro decreased protein levels of PKCa and PKCd at 24 h. Other isoforms and RACK were not aected. At 72 h after treatment with GF and Ro, however, only PKCa was found to be depressed in inhibitor-treated cells ( Figure  9b ). By densitometric analysis, GF was able to decrease PKCa expression by 34% when compared to untreated control (set as 1). Ro had an even greater inhibitory eect on PKC, reducing protein levels by 43%. 
Potentiation of HRG-induced apoptosis by PKC inhibitors is mediated through PKCa
As shown in Figure 6a , PKCa activity was the major PKC activity activated by heregulin in SKBr3 cells. Also as shown in Figure 9 , only PKCa was down-regulated after 72 h treatment with pan-PKC inhibitors at an interval when HRG-induced apoptosis was most evident. To study the role of PKCa in potentiation of HRGinduced apoptosis by PKC inhibitors, we have used Go6976, an inhibitor of classical PKC, (Martiny-Baron et al., 1993) . Since PKCa is the only classical PKC isoform expressed in SKBr3 cells, Go6976 should provide selective inhibition of PKCa in this cell line. As shown in Figure 10a , treatment with Go6976 signi®-cantly enhanced HRG-induced apoptosis, mimicking the eect of broad PKC inhibitors GF and Ro. In contrast, rottlerin, a selective inhibitor of PKCd (Gschwendt et al., 1994) , did not enhance HRG-induced apoptosis. In order to con®rm further the role of PKCa in potentiation of HRG-induced apoptosis by PKC inhibitors, a wildtype PKCa was introduced back into SKBr3 cells while the cells were treated with HRG and GF. As shown in Figure 10b , ectopic expression of wild-type PKCa attenuated the apoptosis generated by HRG and GF. Apoptotic cells were reduced from 42.8% in control transfected cells to 26.8% in PKCa-transfected cells. In these experiments, there was a background of average 12.4% apoptotic cells in all transiently transfected SKBr3 cells. The expression of PKCa in SKBr3 cells transfected with pCDNA3-PKCa and pCDNA3 was veri®ed by Western blot analysis (Figure 10c ). Therefore, these data suggested that inhibition of the PKCa isoform was involved in potentiation of HRG-induced apoptosis by PKC inhibitors.
Discussion
HRGs have a variety of biological roles in both normal and tumor cells. In cells that overexpress HER-2, HRGs are able to inhibit tumor growth through induction of cell cycle arrest, cell dierentiation, or apoptosis. In this report, we have focused on the (b) Average levels of the active form of caspase-7 in HRG-treated cells from three dierent experiments were quanti®ed by densitometric scanning and was normalized based upon b-actin levels. The untreated control was set as 1 arbitrary unit. The asterisk indicates a statistically signi®cant dierence from untreated control. (c) Cells were treated and analysed as described in (a) with anticleaved caspase-9 antibody. (d) Cells were pre-treated with pan-caspase inhibitor for 1 h and then subjected to HRG treatment as described in (a). Cells were harvested for¯ow cytometric analysis as described in Materials and methods. Sub-G1 fractions representing apoptotic cell population were determined based on relative DNA content. Data are presented in mean+s.d. (from two experiments). *Indicates a statistically signi®cant dierence from untreated group; **Denotes a statistically signi®cant dierence from the heregulin-treated group molecular mechanisms by which HRG induces apoptosis in human SKBr3 breast cancer cells. HRG downregulated the anti-apoptotic protein Bcl-2, activated the initiator caspase-9, activated the eector caspase-7, and degraded PARP. Using inhibitors of PKC, evidence was obtained that PKC may participate in a pathway that promotes survival of cancer cells after HRG treatment. Inhibition of PKC further downregulated Bcl-2 protein after treatment with HRG. Among the ®ve PKC isoforms (PKCa, PKCi, PKCz, PKCl, and PKCd) expressed by SKBr3 cells, the PKCa isoform may be particularly important for modulating heregulin-induced apoptosis.
To date, HRG has been found by dierent investigators to induce proliferation, dierentiation, or apoptosis in a variety of normal and transformed human cell lines in vitro and in vivo. Several factors may contribute to these variations including dierences between cell lines, dierent isoforms of HRG, and dierent methodologies for HRG treatment and evaluation (Daly et al., 1997; Weinstein et al., 1998; Aguilar et al., 1999; GuerraVladusic et al., 1999; Le et al., 2000a) . Based on our data and those of other investigators, HRG as a growth factor, similar to c-myc as an oncogene, can exert dual eects on growth either stimulating or inhibiting proliferation. Which eect of HRG will prevail largely depends on cell line, receptor expression, and signaling component. Levels of HER2 expression in the cells are one of the critical factors. Our data con®rmed HRG is mitogenic in cells with low or non-detectable levels of HER2 expression (Figure 1 and unpublished data) . In two of four cell lines with HER2 over-expression, HRG induced apoptosis in a fraction of cells in a dose and time dependent manner. This paper considers in depth the possible mechanisms by which HRG induces apoptosis in HER2-overexpressing SKBr3 cells. As shown in Figure 11 , three signaling pathways have been postulated to transduce apoptotic signals to cells. The inhibition of p38 MAP kinase at a late stage (day 2-3) has been reported to be able to prevent HRG-induced apoptosis (Daly et al., 1999) . Blocking of the p70S6K pathway by rapamycin has been shown to prevent HRG-induced apoptosis (Le et al., 2000b) . In our previous study, we found that HRG induces a sustained JNK activation, while an anti-HER2 antibody ID5 that does not induce apoptosis did not activate JNK (Le et al., 2000b) . A prolonged activation of JNK MAP kinase has been indicated in induction of apoptosis (Davis, 2000) . In (Figure 6a ) that could contribute to the stimulation of cell proliferation and the inhibition of apoptosis. Apoptosis may result from the net impact of signaling on pro-apoptotic pathways mediated by the p70S6K, JNK, and p38 MAP kinases and anti-apoptotic pathways mediated, in part, by PKC and Bcl-2. PKC inhibitors block PKC activation and diminish the survival signals. Therefore, PKC inhibitors could enhance HRG-induced apoptosis as outlined in Figure 11 .
The Bcl-2 family of proteins contains at least eighteen members that have been divided into three subgroups based on their structure. Members of the ®rst subgroup, represented by Bcl-2 and Bcl-xL, have an anti-apoptotic function. Members of the second subgroup, represented by Bax and Bak, as well as members of the third subgroup such as Bid and Bad, are pro-apoptotic molecules (Gottlieb, 2000) . Whether or not apoptosis is initiated depends on the balance of pro-and anti-apoptotic proteins in the cells. A selective decrease in Bcl-2 expression can lead to a lower ratio of anti-apoptotic/pro-apoptotic molecules permitting propagation of a death signal. Weinstein et al. (1998) reported overexpression of HRGb2b under the control of an MMTV promoter was shown to decrease Bcl-2 protein in MCF-7 breast cancer cells. We have observed this phenomenon via a dierent approach. As shown in Figures 2, 5 and 7, treatment of SKBr3 breast cancer cells for 72 h with 1 nM recombinant HRGb1 produced a signi®cant reduction in Bcl-2 levels. These data strongly indicate that down-regulation of Bcl-2 is a direct action of HRG. Downregulation of Bcl-2 protein is well known to promote apoptosis and to sensitize tumor cells to apoptosis induced with chemotherapy or immunotherapy. Constitutive expression of HRGb2 in MCF-7 cells has been shown to markedly increase sensitivity to doxorubicin and etoposide treatment (Harris et al., 1998) . Moreover, our own study revealed that HRG in combination with PKC inhibitors were able to further inhibit Bcl-2 expression (Figure 7) . Interestingly, PKCa has recently been shown to co-localize with Bcl-2 in mitochondrial membranes and to directly phosphorylate wild-type Bcl-2 at serine 70, which could result in increasing resistance to antileukemic chemotherapy and inhibition of apoptosis (Ruvolo et al., 1998) . This may explain why the pan-PKC inhibitors could downregulate Bcl-2 expression and enhance HRG-induced apoptosis. Thus, it is reasonable to postulate that HRG alone or in combination with PKC inhibitors may act as biological modi®er to sensitize tumor cells to apoptosis induced by available therapy.
Apoptosis is mediated by a family of caspases that are activated by processing from its inactive precursor. Caspase-9 and 8 are initiator caspases that are involved in mitochondrial-mediated and death domain-mediated apoptosis, respectively (Gottlieb, 2000) . Caspase-3, -6, and -7 function as eectors of apoptosis. Since HRG was found to decrease Bcl-2 expression and to activate caspase-9 (Figures 2 and 3) , HRG-induced apoptosis is likely to be mediated by release of cytochrome C from mitochondria. Caspase-7 is the only eector caspase activated in HRGinduced apoptosis (Figure 3 ). Caspase-3 and 6 were found not to be activated by HRG treatment in SKBr3 cells with both Western blot analysis and caspase activity assays. Caspase-7 as the only activated eector caspase has been reported in other studies as well. For example, Fas-mediated apoptosis in in human prostatic carcinoma cell lines (ALVA31, DU145 and JCA1) activated caspase-7, but not caspase-3 (Rokhlin et al., 1998) . Only caspase 7 activation is found to cleave kinectin in apoptotic cells (Machleidt et al., 1998) . Caspase-7, but not caspase-3, undergoes proteolytic activation during lovastatin-induced apoptosis in prostate cancer cell line LNCaP (Marcelli et al., 1998) . It has been reported that caspase-7 is able to cleave PARP (Germain et al., 1999) . Our results shown in Figures 3 and 4 further con®rm that caspase-7 is capable of cleaving and degrading PARP. In our experiment, the 85-kDa fragment of PARP could not be detected in HRG-treated cells. It could be hypothesized that PARP degradation continues after its ®rst cleavage. The same anti-PARP antibody was able to detect the smaller band in SKBr3 cells treated with paclitaxel for 48 h (Figure 4) , suggesting that degradation of 85-kDa fragment of PARP is due to HRG treatment. The mechanism is not clear. Poly-(ADP-ribosyl)ation of PARP has been reported to accelerate its proteolysis (Germain et al., 1999) . Whether or not HRG treatment could stimulate this poly(ADP-ribosyl)ation remains to be addressed. Interestingly, PARP degradation with no appearance of its 85-kDa fragment is found in apoptotic Syrian hamster embryo (SHE) cells (Alexandre et al., 2000a) . No induction of caspase-3 activity was noted in apoptotic SHE cells (Alexandre et al., 2000b) . These results along with the data presented in Figures 3 and  4d suggest that although PARP is the common substrate of some caspases, proteases other than caspase-3 (such as caspase-7) may degrade PARP without its 85-kDa fragment that is typically seen in caspase-3-mediated PARP cleavage. HRG-induced apoptosis develops slowly over 72 h and this prolonged interval could make the small PARP fragment more vulnerable to digestion by activated caspase-7.
The PKC family of structurally related isoforms exhibit dierent cofactor requirements, but similar substrate speci®city. Classical PKC isoforms, PKCa, PKCb, and PKCg, are phosphatidyl serine (PS), diacylglycerol (DAG) and Ca 2+ -dependent. Novel PKC isoforms, PKCd, PKCe, PKCy, and PKCZ, also require PS and DAG, but are Ca 2+ -independent. The atypical PKC isoforms, PKCz, PKCi, and PKCl, require PS, but are DAG-and Ca 2+ -independent (Deacon et al., 1997) . PKC isoforms dier in their tissue distribution and localization within the cell, suggesting that each isoform plays a speci®c role in speci®c setting. PKC not only plays a fundamental role in the regulation of cell proliferation and dierentiation, but also in the regulation of cell survival and apoptosis. Activation of PKC may be either proapoptotic or anti-apoptotic depending on the cell type (Deacon et al., 1997) . The results shown in Figure 6 demonstrate that inhibition of PKC function promotes apoptosis in SKBr3 breast cancer cells, suggesting PKC isoforms in this cell line are survival factors.
Our data further demonstrate that inhibition of the PKCa isoform alone is sucient to potentiate HRGinduced apoptosis in SKBr3 cells and wild-type PKCa isoform can rescue the cells from apoptosis induced by HRG and PKC inhibitor (Figure 10 ). These data suggest that the PKCa isoform is a survival factor in SKBr3 cells. These ®ndings are consistent with previous studies that have found that the PKCa isoform appears to be antiapoptotic (Lee et al., 1996; Whelan and Parker, 1998) . PKCa isoform has been found to function as a Bcl-2 kinase to inhibit apoptosis (Ruvolo et al., 1998) . In contrast to the anti-apoptotic isoform PKCa, PKCd is emerging as a pro-apoptotic intermediate in the apoptotic pathway induced by chemicals and irradiation (Emoto et al., 1996; Deacon et al., 1997; Reyland et al., 1999) . However, PKCd appears not to be involved in potentiation of HRG-induced apoptosis by PKC inhibitors based on the data in Figures 9 and 10 .
In summary, HRG-induced apoptosis in HER2-overexpressing SKBr3 breast cancer cells is associated with down-regulation of Bcl-2 protein, activation of caspase-9 and caspase-7, and degradation of PARP. Five PKC isoforms, PKCa, PKCi, PKCz, PKCl, and 
Materials and methods
Cell line and cell culture
The human breast cancer cell lines SKBr3, AU565, MDA-MB-231, MDA-MB-468, and MDA-MB-435 were grown in complete medium, containing RPMI 1640 (GIBCO/BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma, St. Louis, MO, USA), 2 mM Lglutamine, 100 units/ml penicillin and 100 mg/ml streptomycin in humidi®ed air with 5% CO 2 at 378C. MDA-MB-453 was maintained in L15 Leibovitz's complete media. MCF-7 was maintained in DMEM complete media. BT474 and BT483 were maintained in DMEM/F12 (1 : 1) complete media with 5 mg/ml bovine recombinant insulin. All cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). For all experiments, cells were detached with 0.25% Trypsin ± 0.02% EDTA. For cell culture, 2610 5 exponentially growing cells were plated in tissue culture dishes or plates. After culturing overnight in complete medium, cells were pre-treated (if applicable) with PKC inhibitors in complete medium for 1 h. Cells were then treated with heregulin b1 (1 nM) in medium with 10% FBS at 378C for an additional 72 h.
Reagents
PKC inhibitors GF109203, Go6976, and rottlerin were purchased from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA, USA). PKC inhibitor Ro318425, pancaspases inhibitor ± Caspase inhibitor III, caspase-6 inhibitor I, and caspase-3 inhibitor III were obtained from Calbiochem-Novabiochem Corp. (La Jolla, CA, USA). The transfection reagent LipofectAMINE-2000 was purchased from GIBCO/BRL (Grand Island, NY, USA). The expression vector of pCDNA3-PKCa was obtained from Dr CA O'Brian (MD Anderson Cancer Center, Houston, TX, USA). An empty vector pCDNA3 was obtained from Invitrogen (Carlsbad, CA, USA). Recombinant human heregulin b1 was obtained from NeoMarkers, Inc. (Fremont, CA, USA). A Green¯uorescence protein (GFP) vector (pEGFP-F) was purchased from Clontech Laboratories (Palo Alto, CA, USA). Polyclonal antibodies reactive with caspase-7, caspase-3, caspase-6, and caspase-8 were purchased from Oncogene Research Products (Cambridge, MA, USA). Monoclonal antibodies against human PARP and caspase-7 and polyclonal rabbit anti-caspase-3 were obtained from BD PharMingen (San Diego, CA, USA). Anti-PKCz antibody and anti-caspase-3 antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-caspase-8, anti-caspase-9, anti-cleaved caspase-9 antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). A panel of monoclonal antibodies to PKCa, PKCb, PKCg, PKCi, PKCd, PKCe, PKCZ, PKCl, PKCy, RACK1, and DGKy were purchased from Transduction Laboratories (Lexington, KY, USA). Monoclonal antibody to b-actin was obtained from Sigma (St. Louis, MO, USA). Monoclonal anti-human Bcl-2 antibody was purchased from Ancell Corporation (Bayport, MN, USA).
Preparation of total cell lysate and Western immunoblot analysis
The procedures for preparation of total protein and Western immunoblot analysis were performed as described previously (Le et al., 2000a) .
PKC activity assay
The assay employed for the Ca 2+ -and PS-dependent PKC activity was performed as previously described (Ward, et al., 2000) . Brie¯y, the SKBr3 cells were treated with HRG mentioned above and lysed in buer A containing 1% Triton X-100. Lysates were stirred for 15 min at 48C, centrifuged at 14 000 g, and the supernatants were loaded onto 0.5 mL DEAE Sepharose columns (Sigma) equilibrated in buer A. The columns were washed with 2 mL of buer A, and PKC was eluted with 1 mL of buer A containing 0.3 M NaCl. PKC assay mixtures (120 ml) utilized the synthetic peptide [Ser25]PKC19-31 (Bachem Bioscience Inc., King of Prussia, PA, USA) as substrate and contained 20 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 0.2 mM CaCl 2 , 30 mg/ml PS, 6 mM [g-32 P]ATP (5000 ± 8000 c.p.m./pmol), 10 mM [Ser25]PKC19-31 and 5 mg of the eluted sample. A 10-min reaction period at 308C was initiated by the addition of [g-32 P]ATP, and the reaction was terminated on phosphocellulose paper to quantitate 32 P incorporation into the peptide substrate. Because classical PKC (cPKC) is the only cPKC isozyme Figure 11 Proposed model for heregulin-induced apoptosis and the role of PKC inhibitors in SKBr3 breast cancer cells. Heregulin produces both survival signals (PKC) and apoptotic signals (p38 and JNK MAP kinases and p70S6K pathways). The apoptotic signals prevail in cells after heregulin treatment and downregulate Bcl-2 protein, activate caspase-9 and caspase-7, and cleave the PARP. PKC inhibitors reduce PKCa expression and activity, which diminishes the survival signal and further enhances heregulin-induced apoptosis. + indicates stimulation. 6 means inhibition expressed in the cells (see Results), the assay directly measures cPKC-activity in this system. The cPKC inhibitor Go6976 (100 nM) was included in the assay mixtures that measured background kinase activity. Assays were performed in triplicate, and results shown were reproducible in independent experiments.
Cell cycle analysis
Cell cycle distribution was analysed by¯ow cytometry. Cells treated with HRG or PKC inhibitors (if applicable) for 72 h were trypsinized, washed once with PBS, and ®xed overnight in 70% ethanol. Fixed cells were centrifuged at 3006g for 10 min and washed with PBS. Cell pellets were resuspended in PBS containing 50 mg/ml of RNase A and 50 mg/ml propidium iodide and incubated for 20 min at 378C with gentle shaking. Stained cells were ®ltered through nylon mesh (41 mM) and analysed on a Coulter¯ow cytometer XL-MCL (Coulter Corporation, Miami, FL, USA) for relative DNA content based on red¯uorescence levels. Doublets and cell debris were excluded from the DNA histograms. The percentages of sub-G1 cell population were determined based on relative DNA content. The percentages of cells in dierent cell cycle compartments were determined using the MULTI-CYCLE software program (Phoenix Flow Systems, San Diego, CA, USA).
DNA laddering analysis
DNA fragmentation as a result of apoptotic cell death following HRG and PKC inhibitors in SKBr3 cells was performed as described before (Le et al., 1998) . Brie¯y, treated or untreated SKBr3 cells were trypsinized. Detached cells were centrifuged, and lysed for 30 min on ice in buer containing 10 mM Tris, 1 mM EDTA and 0.2% Triton. The lysate was centrifuged at 14 000 g for 10 min. The pellet and the supernatant fractions were resuspended in the above lysis buer and incubated with 200 mg/ml proteinase K for 1 h at 508C and extracted with phenol and chloroform. Then DNA was precipitated overnight at 7208C in one volume of ethanol and 0.13 m NaCl. After treatment with 1 mg/ml DNase free RNase A for 1 h at 508C, the DNA was electrophoresed in 1.8% agarose gel.
Transient transfection
SKBr3 cells grown in 60 mm dishes were transfected in duplicate with 8 mg of the appropriate expression plasmid plus 2 mg of pGFP vector using 15 ml of LipofectAMINE-2000 (GIBCO BRL) according to the manufacturer's instruction. At 16 h after transfection, a portion of cells were harvested and checked with the GFP expression under a¯u orescence microscope (Leica). Another portion of transfected cells were fed fresh media and treated with HRG or/ and PKC inhibitors. Cells were harvested 72 h after HRG and PKC inhibitor treatment. The cell lysates were subjected to Western blot analysis.
Preparation of Adenovirus-caspase-7 (Ad-casp-7)
Construction and veri®cation of Ad-casp-7 were reported previously (Marcelli et al., 1999) . Large-scale production of high-titer Ad-casp-7 was performed by growing 293 cells on improved Eagle's MEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 units/ml penicillin, 50 mg/ml streptomycin and 1% Fungizone (Life Technologies). The virus was puri®ed twice using cesium-chloride density gradient centrifugation. The viral vector was then dialyzed for 8 h at 48C against a buer containing 10 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , and 10% glycerol and was stored at 7808C.
Infection with Ad-casp-7
Four610
5 SKBr3 cells were seeded in 6-well cell culture plate overnight. Cells were then infected with Ad-casp-7 at dierent multiplicity of infection (MOI) or at 30 MOI with gentle shaking at 378C incubator for 1.5 h. HRG1b was added (if applicable) to the cells without washing. PKC inhibitor was added to the cells 30 min before addition of HRG. Cells were incubated at 378C for another 72 h and then were harvested and analysed for cell cycle analysis and caspase-7, Bcl-2, and PARP protein expression as described above.
Statistical analysis
The two-tailed Student's t-test was used to compare two dierent groups. Values with P50.05 were considered signi®cant.
